Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)

Summary

The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.

Conditions

• Asthma
• Lung Diseases

Interventions

DRUG

Placebo

Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.

DRUG

Nedocromil

Four 2 mg puffs bid + two 90 Og puffs albuterol prn

DRUG

Budesonide

Two 100 Og puffs bid + two 90 Og puffs albuterol prn.

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• CAMP Steering Committee

  collaborator UNKNOWN

• Johns Hopkins Bloomberg School of Public Health

  lead OTHER

Principal Investigators

• N. F. Adkinson, MD · Johns Hopkins University

• Anne Fuhlbrigge, MD, MS · Brigham and Women's Hospital

• H. W. Kelly, PharmD · University of New Mexico

• Padmaja Subbarao, MD, MSc · The Hospital for Sick Children

• Paul Williams, MD · Asthma, Inc.

• Robert Strunk, MD · Washington University School of Medicine

• Stanley Szefler, MD · National Jewish Health

• James Tonascia, PhD · Johns Hopkins University

• Robert Zeiger, MD, PhD · University of California, San Diego

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

5 Years

Max Age

12 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1991-09-30

Primary Completion

1999-10-31

Completion

2012-03-31